Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE I/Ib, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF ABTL0812 IN PATIENTS WITH ADVANCED SOLID TUMOURS

NCT02201823 is registered in ClinicalTrials.gov with Ability Pharmaceuticals SL as lead sponsor.

NCT NCT02201823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02201823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE I/Ib, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF ABTL0812 IN PATIENTS WITH ADVANCED SOLID TUMOURS
Lead sponsor
Ability Pharmaceuticals SL
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
April 30, 2015
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer